Baxter International (BAX)
Health Care · Medical Devices and Supplies · NYSE
Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home.
What Baxter International does
Baxter International is a global medical technology company that provides a broad portfolio of essential healthcare products. Its offerings include hospital and renal care solutions, such as dialysis therapies, intravenous (IV) solutions, infusion systems, and specialized surgical and pharmaceutical products. The company focuses on addressing critical care needs in hospitals, clinics, and home settings.
Themes: renal care / dialysis, hospital solutions, infusion therapy, surgical technology, home healthcare
Fundamentals
- Price$26.49 as of 2026-08-24 close
- Market cap$13.7B as of 2026-08-24
- 1-year return+7.9% 2025-08-22 close $24.54 → 2026-08-24 close $26.49
- P/En/a negative earnings
- Net margin-9.3% as of 2026-08-24
- Gross margin+30.7% as of 2026-08-24
- ROE-16.6% as of 2026-08-24
- Debt / equity1.52 as of 2026-08-24
- Revenue growth (YoY)+5.4% as of 2026-08-24
- Revenue CAGR (3y)+3.8% SEC XBRL
- Beta0.92 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.2%; 1-year non-decreasing per-share dividend streak (SEC XBRL).
How BAX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
BAX is not currently in any published Top 10 list. Its scores are below.
Long-term score
35.7 #893 of 987 scored · #54 of 57 in Health Care
Long-term trend 65th (a strong uptrend, with buyers in control) and valuation 59th (price to book 2.2); weakest is profitability (3rd, return on equity -16.6%, operating margin -2.3%).
Short-term score
66.2 #32 of 1,704 scored · #13 of 240 in Health Care
Catalysts 78th: the analyst consensus rating has improved toward "buy" since the prior reading; trend 67th: a strong uptrend, with buyers in control; weakest is setup 59th: over the past year its closes ranged, and it has retraced roughly a quarter of its move over the past year — 16% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, BAX's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 105%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings were not positive that year
- Free-cash-flow payout105% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Baxter International looks technically
Baxter International (BAX) is trading 32.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day high about 14 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 32.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +32.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $23.57 | $23.57 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $19.93 | $19.93 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 23.71. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal | 28 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 37.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 56.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($25.75 to $28.38) — its "stochastic" reading is 22 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 22.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.00 | $30.00 |
|---|---|---|
| From the 52-week high | it is 12.2% below its 52-week high (its highest price of the past year) | -12.2% |
| Above the 52-week low | it is 67.5% above its 52-week low (its lowest price of the past year) | +67.5% |
| Below the 52-week high | it is 12.2% below its highest point of the past year | 12.2% |
| Since a 20-day breakout | it made a new 20-day high about 14 trading days ago | 14 sessions |
| Since a 55-day breakout | it made a new 55-day high about 14 trading days ago | 14 sessions |
| All-time high | its highest closing price on record is $95.19 (set on 2020-04-20) | $95.19 |
| Given back of the 52-week move | over the past year its closes ranged ($15.80 to $28.35), and it has given back roughly a quarter of its rise from last year’s low — 16% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $20.19 to $20.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 16.0% |
| From the all-time high | it is 72.3% below its all-time high | -72.3% |
| Nearest price level | it is trading 6.5% above a support level at $24.63 — a price it turned at four times since 2025-08-20, most recently on 2025-10-03. Since 2024-08-21 it has 8 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.5% |
| All-time low | its lowest closing price on record is $9.88 (set on 2003-04-01) | $9.88 |
| Above the all-time low | it is 166.7% above its all-time low | +166.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 45th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9614 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9614 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $24.11 and $29.00 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $24.11 – $26.55 – $29.00 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 6.7 daily ranges above its 200-day average price (32.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.65× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 2.1% since the prior reading | +2.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.02 toward buy |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Open gap | it gapped 17.4% above the previous close 16 sessions ago and has not traded back through the level it left behind at 24.77 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +17.4% |
| Gap filled | a 2.8% gap down opened on 2026-08-20 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.13% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.3 percentage points (the stock gained 18.6% while the market gained 2.3%) | +16.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 35.3 percentage points (the stock gained 38.4% while the market gained 3.1%) | +35.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 11.0 percentage points (the stock gained 22.1% while the market gained 11.1%) | +11.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.0 percentage points (the stock gained 10.4% while the market gained 20.5%) | -10.0% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.3% of the share price. | +20.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 30% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $20.27 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +30.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $27.07 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | -2.7% |
Price levels it has turned at before
BAX last closed at $26.34 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.63 | Support | 6.5% below the last close | turned there four times · 2025-08-20 to 2025-10-03 |
| $28.48 | Resistance | 8.1% above the last close | turned there twice · 2024-12-19 to 2024-12-30 |
| $23.61 | Support | 10.4% below the last close | turned there three times · 2025-10-20 to 2026-07-17 |
| $29.28 | Resistance | 11.2% above the last close | turned there three times · 2025-06-03 to 2025-07-28 |
| $29.95 | Resistance | 13.7% above the last close | turned there four times · 2025-02-12 to 2026-07-30 |
| $21.39 | Support | 18.8% below the last close | turned there six times · 2025-08-01 to 2026-07-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $23.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $25.70 and $27.97 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $30.00.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.77 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$28.73 range $23.00 – $40.00; median $28.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BAX
- Consensus EPS estimate$0.5189 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant leverage and reliance on debt obligations","Operational and financial performance variability impacting net margins","Foreign currency exchange rate fluctuations affecting international operations"]
What changed in the latest 10-Q
AI-assisted comparison of BAX's 10-Q filed 2026-04-30 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Annual Report (Form 10-K for year ended December 31, 2025) instead of 2024 Annual Report
- Mention of three months ended March 31, 2026 and 2025 as comparison periods
- Reference to 'ONGOING BUSINESS TRANSFORMATION' in section heading
- Specific after-tax cash proceeds amount of approximately $3.2 billion (newer filing)
- Description of 'Baxter Growth and Performance system' launched in October 2025 as high performance business system grounded in continuous improvement
- Mention of 'thoughtful exploration of artificial intelligence initiatives' as part of operating model evolution
- Note 10 reference for restructuring information in newer filing
- Statement that 'During 2025, we initiated voluntary corrections' for Novum LVP (versus April 24, 2025 specific date in older filing)
- Mention of 'In July 2025, we elected to temporarily stop distributing' language in newer filing
- Reference to adjustments to Novum LVP estimates in first quarter of 2026 that were not material
- Reference to Supreme Court's decision to invalidate tariffs levied under the International Emergency Economic Powers Act
- Mention of refund requests submitted in second quarter of 2026 for eligible tariff amounts
- Reference to Section 122 duties imposed following judicial review of certain tariffs
- Mention of 'conflict in Iran and the potential for escalation'
- Discussion of 'Kidney Care MSA sales' in non-GAAP measures section
- Removed:
- Reference to 'three and nine months ended September 30, 2025 and 2024' comparison periods
- Details of EPA agreement date (August 12, 2024)
- Aggregate purchase price of $3.80 billion figure
- Reference to $3.71 billion pre-tax cash proceeds at closing
- Reference to $99 million purchase price reduction in third quarter 2025
- Reference to expected payment to Carlyle in fourth quarter 2025
- Statement that '$3.81 billion of short- and long-term indebtedness' was repaid as of September 30, 2025
- Reference to 'discontinued operations' treatment in financial statements
- Reference to 2024 Annual Report
- Description of implementation of operating model in third quarter 2023
- Details about three reportable segments (Medical Products & Therapies, Healthcare Systems & Technologies, Pharmaceuticals)
- Separate section heading 'Implementation of Operating Model and Resulting Segment Change'
- Sale of BioPharma Solutions (BPS) business details (September 29, 2023, $3.96 billion, debt repayment specifics)
- Separate 'Hurricane Helene' section heading with detailed facility damage and recovery timeline
- Specific dates for Novum LVP correction initiations (April 24, 2025, May 20, 2025, July 2025, August 2025)
- Specific technical details about under-infusion in standby mode, bolus infusion risks, and set misloading risks
- Reference to reserve recorded in second quarter as 'not material'
- Statement that 'timing of this continued ship and installation hold remains uncertain, we currently expect it to be in place beyond 2025'
- Note 16 reference for segment financial information in older filing
- Notes 2 and 5 references in older filing
- Language about being 'in the process of implementing select tariff offsets'
- Reworded:
- 'COMPLETED STRATEGIC ACTIONS' changed to 'COMPLETED STRATEGIC ACTION; ONGOING BUSINESS TRANSFORMATION'
- 'On January 31, 2025, we completed the sale of our Kidney Care segment' vs. older detailed EPA narrative now condensed
- 'we have undertaken certain restructuring actions (and intend to undertake additional actions)' changed from 'we have begun to undertake certain restructuring actions (and intend to undertake additional actions)'
- Evolution description reworded: 'continue to evolve our operating model to better align decision-making, cost structure, and commercial execution' vs. older 'implementation of an operating model intended to simplify and streamline'
- Supply chain challenges introduced with 'including, as a result of adverse impacts from significant weather events like Hurricane Helene' integrated into main text versus separate section
- Tariff language expanded with references to Supreme Court decision, refund requests, Section 122 duties, and Court of International Trade
- Reference to 'responses from other jurisdictions' and 'geopolitical events or conflicts' now includes specific mention of 'conflict in Iran'
- 'Our Spectrum IQ large volume pump remains available as an alternative option' vs. 'is generally available as an alternative option'
- 'We regularly review these estimates (including those associated with any future additional corrections and customer returns or exchanges), which may be subject to additional change in the future' added in newer filing
- 'In the first quarter of 2026, we adjusted certain estimates associated with these Novum LVP corrections that were not material' added as update
- Notes:
- Older filing text ends mid-sentence ('including a pr') which limits complete comparison of Supply Constraints section
- Newer filing text also appears truncated at 'Net income (loss) attributable to Baxter stockholders f'
- Comparison period differences (three months ended March 31 vs. three and nine months ended September 30) reflect different quarterly filings, not necessarily discrete changes in disclosure
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for BAX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 7 matched disclosures for BAX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding BAX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 147,926,426
- Reported value $2,485,356,670
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BAX had 32,667,256 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BAX had 6.32% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.34 days to cover at the same settlement.
- Reported short interest (shares) 32,667,256
- Short interest (% of shares outstanding) 6.32%
- Prior settlement (shares) 36,839,907
- Reported change -11.33%
- Days to cover (reported) 4.34
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fresenius Medical Care (FMS)
- Becton Dickinson (BDX)
- Medtronic (MDT)
- B. Braun Melsungen
- DaVita (DVA)
- ICU Medical (ICUI)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BAX vs…
Frequently asked questions
What does Baxter International (BAX) do?
Baxter International is a global medical technology company that provides a broad portfolio of essential healthcare products. Its offerings include hospital and renal care solutions, such as dialysis therapies, intravenous (IV) solutions, infusion systems, and specialized surgical and pharmaceutical products. The company focuses on addressing critical care needs in hospitals, clinics, and home settings.
What sector is Baxter International (BAX) in?
Baxter International (BAX) is classified in the Health Care sector. Its industry is Medical Devices and Supplies. It trades on NYSE.
Does BAX pay a dividend?
Yes — Baxter International (BAX) pays a dividend, with an indicated yield of about 3.22% and 1-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Baxter International's (BAX) competitors?
Notable peers of Baxter International (BAX) include Fresenius Medical Care, Becton Dickinson, Medtronic, B. Braun Melsungen and DaVita. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in BAX?
Yes — we hold 7 matched STOCK Act disclosures for BAX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Baxter International (BAX) overbought or oversold right now?
Baxter International (BAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BAX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.